Antibiotic prescription during the COVID-19 pandemic: A biphasic pattern.

Szczegóły
Comments

Tytuł:: Antibiotic prescription during the COVID-19 pandemic: A biphasic pattern.
Autorzy:: Abelenda-Alonso G; Department of Infectious Diseases, Bellvitge University Hospital, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Padullés A; Department of Pharmacy, Bellvitge University Hospital, Barcelona, Spain.
Rombauts A; Department of Infectious Diseases, Bellvitge University Hospital, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Gudiol C; Department of Infectious Diseases, Bellvitge University Hospital, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; Spanish Network for Research in Infectious Diseases, Madrid, Spain.
Pujol M; Department of Infectious Diseases, Bellvitge University Hospital, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.
Alvarez-Pouso C; Department of Infectious Diseases, Bellvitge University Hospital, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Jodar R; Department of Pharmacy, Bellvitge University Hospital, Barcelona, Spain.
Carratalà J; Department of Infectious Diseases, Bellvitge University Hospital, Barcelona, Spain.; Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.; University of Barcelona, Barcelona, Spain.; Spanish Network for Research in Infectious Diseases, Madrid, Spain.
Źródło:: Infection control and hospital epidemiology [Infect Control Hosp Epidemiol] 2020 Nov; Vol. 41 (11), pp. 1371-1372. Date of Electronic Publication: 2020 Jul 30.
Typ publikacji:: Letter; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Publication: Jan. 2015- : Cambridge : Cambridge University Press
Original Publication: [Thorofare, N.J. ] : SLACK Inc., c1988-
MeSH Terms:: Coronavirus Infections*/complications
Pandemics*
Pneumonia, Viral*/complications
Anti-Bacterial Agents/*therapeutic use
Drug Prescriptions/*statistics & numerical data
Hospitals, University/*statistics & numerical data
Pneumonia/*drug therapy
Antimicrobial Stewardship ; COVID-19 ; Cross-Sectional Studies ; Humans ; Pneumonia/virology ; Spain
References:: Infect Control Hosp Epidemiol. 2020 Jun;41(6):744-745. (PMID: 32167442)
JAMA. 2020 May 26;323(20):2052-2059. (PMID: 32320003)
Clin Infect Dis. 2020 May 01;:. (PMID: 32361747)
Clin Microbiol Infect. 2011 May;17(5):738-46. (PMID: 20825436)
Lancet Respir Med. 2020 May;8(5):475-481. (PMID: 32105632)
Clin Microbiol Infect. 2020 Jul;26(7):808-810. (PMID: 32360446)
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67. (PMID: 31573350)
Substance Nomenclature:: 0 (Anti-Bacterial Agents)
Entry Date(s):: Date Created: 20200731 Date Completed: 20201109 Latest Revision: 20210110
Update Code:: 20240104
PubMed Central ID:: PMC7426604
DOI:: 10.1017/ice.2020.381
PMID:: 32729437
: Raport

Erratum in: Infect Control Hosp Epidemiol. 2020 Nov;41(11):1373. (PMID: 32845236)

Informacja